Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (15)

2024

  1. Risk Stratification in Pulmonary Veno-Occlusive Disease

    Archivos de Bronconeumologia, Vol. 60, Núm. 5, pp. 321-323

2023

  1. Usefulness of genetics for clinical reclassification and refinement of prognostic stratification in pulmonary arterial hypertension

    Revista Espanola de Cardiologia, Vol. 76, Núm. 6, pp. 460-467

2022

  1. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

    Scientific Reports

  2. Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry

    Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 260-266

  3. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

    Scientific reports, Vol. 12, Núm. 1, pp. 5289

2021

  1. Azole and amphotericin B MIC values against aspergillus fumigatus: High agreement between spectrophotometric and visual readings using the EUCAST EDef 9.3.2 procedure

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 1

  2. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain

    Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1170.e1-1170.e7

  3. From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?

    Advances in Therapy, Vol. 38, Núm. 4, pp. 1860-1875

2019

  1. Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry

    International Journal of Cardiology, Vol. 275, pp. 158-164

2018

  1. Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival

    Revista Espanola de Cardiologia, Vol. 71, Núm. 2, pp. 117-118

2016

  1. Founder mutation C.3344C>t(p.Pro1115Leu) in the EIF2KA4 gene in iberian romani patients with pulmonary veno-occlusive disease: A warning for our daily practice

    Archivos de Bronconeumologia

2015

  1. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies

    Clinical Genetics, Vol. 88, Núm. 6, pp. 579-583

2014

  1. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?

    International Journal of Cardiology, Vol. 171, Núm. 1, pp. 15-23

2013

  1. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation

    Clinical Transplantation, Vol. 27, Núm. 6

2012

  1. Steroid Withdrawal during 5 years following heart transplantation, and the relationship between steroid dosage at 1-year follow-up and complications during the next 2 years: Results from the restco study

    Transplantation Proceedings